PMID- 37058057
OWN - NLM
STAT- MEDLINE
DCOM- 20230418
LR  - 20231002
IS  - 1536-5964 (Electronic)
IS  - 0025-7974 (Print)
IS  - 0025-7974 (Linking)
VI  - 102
IP  - 15
DP  - 2023 Apr 14
TI  - Analysis of adverse events and quality of life in high-grade serous ovarian 
      cancer patients with Olaparib maintenance therapy: A single-center study in 
      China.
PG  - e33434
LID - 10.1097/MD.0000000000033434 [doi]
LID - e33434
AB  - Olaparib showed good efficacy and tolerability in the maintenance treatment of 
      patients with initial therapy or high-grade serous recurrent ovarian cancer 
      patients. This study aimed to analyze adverse events (AEs) of patients taking 
      Olaparib and the quality of life (QoL) with Olaparib in 1 center of China. The 
      study included 98 patients who received Olaparib and 210 patients without 
      Olaparib from July 2018 to October 2021 for high-grade serous ovarian cancer in 
      the Gynecology Oncology Department of Jiangsu Provincial Hospital. Information of 
      clinicopathologic characteristics was collected from medical records. Then, we 
      used the QLQ-C30 and Quality of Life Ovarian Cancer 28 Questionnaire (QLQ-OV28) 
      to determine the QoL of 98 patients with and 210 patients without Olaparib. Among 
      all 98 patients with Olaparib, 66 patients in first-line and 32 patients in more 
      than second-line treatment. Regarding the best objective response with Olaparib 
      maintenance in 78 patients with partial remission from most recent chemotherapy, 
      3 (3.84%) patients showed complete response (CR) and 6 (7.69%) showed as partial 
      response (PR), whereas stable disease was observed in 42 patients (53.84%) and 27 
      patients (34.6%) showed as progression disease. AEs of Grade 3 and more were: 
      anemia in 16 patients (16.32%), neutropenia in 20 patients (20.40%), 
      thrombocytopenia in 4 patients (4.08%), and headache in 4 patients (4.08%). Dose 
      reduction and drug discontinuation accounted for 73.40% and 20.40%, respectively. 
      Olaparib as maintenance therapy increased QoL on all functioning domains and 
      several symptom domains. Consistent with previous clinical trials, Olaparib 
      maintenance therapy was proved safe and effective. Most patients may experience 
      Grade 1 and 2 AEs. Olaparib maintenance therapy can increase QoL in several 
      domains.
CI  - Copyright (c) 2023 the Author(s). Published by Wolters Kluwer Health, Inc.
FAU - Jiang, Yi
AU  - Jiang Y
AD  - Department of Gynaecology, The First Affiliated Hospital with Nanjing Medical 
      University, Nanjing, Jiangsu, China.
FAU - Xu, Ting
AU  - Xu T
AD  - Department of Gynaecology, The First Affiliated Hospital with Nanjing Medical 
      University, Nanjing, Jiangsu, China.
FAU - Yuan, Lin
AU  - Yuan L
AD  - Department of Gynaecology, The First Affiliated Hospital with Nanjing Medical 
      University, Nanjing, Jiangsu, China.
FAU - Zhang, Lin
AU  - Zhang L
AD  - Department of Gynaecology, The First Affiliated Hospital with Nanjing Medical 
      University, Nanjing, Jiangsu, China.
FAU - Ruan, Xinjia
AU  - Ruan X
AD  - State Key Laboratory of Natural Medicines, Research Center of Biostatistics and 
      Computational Pharmacy, China Pharmaceutical University, Nanjing, Jiangsu, China.
FAU - Wu, Shan
AU  - Wu S
AD  - Department of Gynaecology, The First Affiliated Hospital with Nanjing Medical 
      University, Nanjing, Jiangsu, China.
FAU - Meng, Huangyang
AU  - Meng H
AD  - Department of Gynaecology, The First Affiliated Hospital with Nanjing Medical 
      University, Nanjing, Jiangsu, China.
FAU - Cheng, Wenjun
AU  - Cheng W
AUID- ORCID: 0000-0002-5600-9982
AD  - Department of Gynaecology, The First Affiliated Hospital with Nanjing Medical 
      University, Nanjing, Jiangsu, China.
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Medicine (Baltimore)
JT  - Medicine
JID - 2985248R
RN  - 0 (Antineoplastic Agents)
RN  - WOH1JD9AR8 (olaparib)
SB  - IM
MH  - Humans
MH  - Female
MH  - *Antineoplastic Agents/adverse effects
MH  - Quality of Life
MH  - Maintenance Chemotherapy
MH  - *Ovarian Neoplasms/pathology
MH  - Neoplasm Recurrence, Local/drug therapy
PMC - PMC10101289
COIS- The authors have no conflicts of interest to disclose.
EDAT- 2023/04/15 06:00
MHDA- 2023/04/18 06:42
PMCR- 2023/04/14
CRDT- 2023/04/14 10:13
PHST- 2023/04/18 06:42 [medline]
PHST- 2023/04/14 10:13 [entrez]
PHST- 2023/04/15 06:00 [pubmed]
PHST- 2023/04/14 00:00 [pmc-release]
AID - 00005792-202304140-00047 [pii]
AID - 10.1097/MD.0000000000033434 [doi]
PST - ppublish
SO  - Medicine (Baltimore). 2023 Apr 14;102(15):e33434. doi: 
      10.1097/MD.0000000000033434.